Illumina Inc. (NASDAQ:ILMN) was upgraded by stock analysts at Vetr from a “sell” rating to a “buy” rating in a research report issued on Monday. The brokerage presently has a $198.61 target price on the life sciences company’s stock. Vetr‘s price target points to a potential upside of 9.60% from the company’s previous close.
Several other research analysts have also commented on the company. Zacks Investment Research raised Illumina from a “sell” rating to a “hold” rating in a research report on Monday, July 4th. Cantor Fitzgerald reissued a “hold” rating on shares of Illumina in a research report on Wednesday, June 29th. Mizuho raised their price objective on Illumina from $138.00 to $148.00 and gave the company a “neutral” rating in a research report on Wednesday, July 27th. Citigroup Inc. raised their price objective on Illumina from $175.00 to $190.00 and gave the company a “buy” rating in a research report on Monday, September 12th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $161.00 price objective on shares of Illumina in a research report on Friday, July 15th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and twelve have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $164.94.
Illumina (NASDAQ:ILMN) opened at 181.22 on Monday. The firm has a market capitalization of $26.57 billion, a PE ratio of 62.06 and a beta of 0.47. The stock’s 50 day moving average price is $173.36 and its 200 day moving average price is $155.68. Illumina has a 52-week low of $127.10 and a 52-week high of $196.47.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.13. Illumina had a return on equity of 23.69% and a net margin of 18.73%. The firm had revenue of $600 million for the quarter, compared to analysts’ expectations of $31.91 million. During the same quarter last year, the firm earned $0.80 earnings per share. The firm’s revenue for the quarter was up 11.3% compared to the same quarter last year. Analysts expect that Illumina will post $3.53 earnings per share for the current year.
In other news, Director Robert S. Epstein sold 300 shares of the stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $174.29, for a total transaction of $52,287.00. Following the completion of the sale, the director now owns 6,924 shares in the company, valued at approximately $1,206,783.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Charles Dadswell sold 8,632 shares of the stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $155.00, for a total value of $1,337,960.00. Following the sale, the senior vice president now owns 40,248 shares of the company’s stock, valued at approximately $6,238,440. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.
Several large investors have recently made changes to their positions in the stock. Glenmede Trust Co. NA increased its stake in shares of Illumina by 26.2% in the first quarter. Glenmede Trust Co. NA now owns 3,660 shares of the life sciences company’s stock worth $593,000 after buying an additional 760 shares during the period. Commonwealth Equity Services Inc increased its stake in shares of Illumina by 2.4% in the first quarter. Commonwealth Equity Services Inc now owns 9,046 shares of the life sciences company’s stock worth $1,466,000 after buying an additional 215 shares during the period. Aperio Group LLC increased its stake in shares of Illumina by 5.8% in the first quarter. Aperio Group LLC now owns 37,664 shares of the life sciences company’s stock worth $6,106,000 after buying an additional 2,063 shares during the period. Virginia Retirement System bought a new stake in shares of Illumina during the first quarter worth approximately $385,000. Finally, IFP Advisors Inc increased its stake in shares of Illumina by 215.6% in the first quarter. IFP Advisors Inc now owns 1,133 shares of the life sciences company’s stock worth $184,000 after buying an additional 774 shares during the period. Institutional investors own 95.22% of the company’s stock.
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.